Gemifloxacin is a new quinolone and, like moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin, is more potent in vitro than ciprofloxacin or ofloxacin against Gram-positive aerobes. Gemifloxacin was the most potent of the quinolones tested against streptococci and most ciprofloxacin-resistant pneumococci were susceptible to gemifloxacin. Gemifloxacin, like moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin, was more potent than ciprofloxacin or ofloxacin against all staphylococci and many ciprofloxacin-resistant isolates were susceptible to these quinolones. Against Gram-negative aerobes gemifloxacin was as potent as or slightly less potent than ciprofloxacin, and isolates resistant to ciprofloxacin were also resistant to gemifloxacin and to moxifloxacin, trovafloxacin and grepafloxacin. Gemifloxacin was also the most potent quinolone against Gram-positive anaerobes and fusobacteria but trovafloxacin was the most potent agent tested against other Gram-negative anaerobes. 
Introduction
Since the introduction of the quinolones ciprofloxacin and ofloxacin, there has been a small, but significant, increase in the number of resistant clinical isolates of species previously susceptible to these agents. The early quinolones had a broad spectrum of activity but were typically highly potent against Gram-negative species and less active against Gram-positive species. Many new broad-spectrum quinolones have been developed, some of which, such as sparfloxacin and tosufloxacin, are more potent than ciprofloxacin against Gram-positive species but less potent against Gram-negative species. 1 More recently, quinolones have been developed with good activity against both Gram-positive and Gram-negative species. 2 In this study we compared the in vitro potency of gemifloxacin, moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin with that of ciprofloxacin and ofloxacin against a wide range of clinically important bacteria.
Materials and methods

Antimicrobial agents
The following antimicrobial agents were tested as powders of known potency: gemifloxacin (SmithKline Beecham, Harlow, UK), ciprofloxacin and moxifloxacin (Bayer, Wuppertal, Germany), grepafloxacin (Glaxo Wellcome, Uxbridge, UK), clinafloxacin (Parke Davis, Eastleigh, UK), trovafloxacin (Pfizer, Sandwich, UK), ofloxacin (Hoechst Marion Roussel, Uxbridge, UK) and nalidixic acid (Sanofi Winthrop, Guildford, UK). They were provided by their respective manufacturers. Susceptibility breakpoints recommended by the BSAC, 3 or calculated as tentative breakpoints from the BSAC formula 3 where no breakpoint is given, were 1 mg/L for ciprofloxacin, moxifloxacin (tentative), ofloxacin and trovafloxacin (tentative), 0.5 mg/L for grepafloxacin (tentative) and clinafloxacin (tentative), 0.25 mg/L for gemifloxacin (tentative) and 16 mg/L for nalidixic acid.
Bacterial strains
The organisms included in the study were all clinical isolates from St Thomas' Hospital and were selected to include representatives of the different species commonly isolated from specimens. The isolates were further selected to include, where possible, isolates known to be resistant to ciprofloxacin and isolates resistant to nalidixic acid but susceptible to ciprofloxacin, based on BSAC breakpoints. The organisms were collected over a 10 year period and the collection continuously updated. The following control organisms were included: Escherichia coli NCTC 10418,
Results
The range of MICs, MIC 50 and MIC 90 for each species are listed in Tables I-IV . Gemifloxacin was the most potent of the agents against all streptococci (Table I ) and was two-to four-fold more potent than clinafloxacin, moxifloxacin, trovafloxacin and grepafloxacin. Ciprofloxacin-resistant 2 isolates of Streptococcus pneumoniae were usually susceptible to gemifloxacin although the seven highly ciprofloxacin-resistant isolates (MICs 64-128 mg/L) were also resistant to all the new agents (Table I) . Gemifloxacin was also the most potent of the agents against ciprofloxacinsusceptible enterococci but none of the agents had useful activity against ciprofloxacin-resistant enterococci (Table I) . Gemifloxacin was slightly more potent than moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin, all of which were much more potent than ciprofloxacin or ofloxacin, against all staphylococci (Table I) . Many ciprofloxacin-resistant staphylococci were susceptible to gemifloxacin, moxifloxacin and trovafloxacin, although the ciprofloxacin-resistant isolates were less susceptible than ciprofloxacin-susceptible ones (Table I) .
For Enterobacteriaceae (Table II) results have been divided, where appropriate, into the following groups: (i) nalidixic acid-susceptible isolates; (ii) nalidixic acid- resistant but ciprofloxacin-susceptible isolates; and (iii) nalidixic acid-and ciprofloxacin-resistant isolates. Gemifloxacin was as potent as or slightly less potent than ciprofloxacin against these isolates, as were trovafloxacin, moxifloxacin and grepafloxacin. Ofloxacin was the least potent and clinafloxacin the most potent agent. Isolates that were resistant to nalidixic acid, but susceptible to ciprofloxacin, were less susceptible to all the agents than were nalidixic acid-susceptible isolates. Those isolates resistant to ciprofloxacin were also resistant to gemifloxacin and the other agents, although some of the resistant strains were susceptible to clinafloxacin in that MICs, although higher than normal, still fell below the breakpoint.
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All the agents were highly active against isolates of Aeromonas spp.; clinafloxacin and ciprofloxacin were slightly more potent than the others (Table III) . Against isolates of Acinetobacter spp. and Stenotrophomonas maltophilia, gemifloxacin, moxifloxacin, trovafloxacin, grepafloxacin and clinafloxacin were more potent than ciprofloxacin, and many isolates resistant to ciprofloxacin were susceptible to these agents. There were small differences between the agents against other non-fermenting Gram-negative aerobes but gemifloxacin, trovafloxacin, moxifloxacin, grepafloxacin and ofloxacin were all as potent as or slightly less potent than ciprofloxacin. Clinafloxacin was again the most potent agent against these non-fermentative Gram-negative aerobes (Table III ). All Abbreviations as in Tables I and II isolates of H. influenzae and Moraxella catarrhalis were highly susceptible to all the agents, as were nalidixic acidsusceptible isolates of Neisseria gonorrhoeae. However, gemifloxacin, clinafloxacin and trovafloxacin were more potent than ciprofloxacin, moxifloxacin, grepafloxacin and ofloxacin against nalidixic acid-resistant N. gonorrhoeae (Table III) . Against anaerobic bacteria there were differences between the agents depending on the species tested (Table  IV) . Clinafloxacin was the most potent against Gramnegative anaerobes and trovafloxacin was generally more potent than the other agents against the B. fragilis group. Trovafloxacin, along with moxifloxacin, was also slightly more potent than gemifloxacin against Prevotella and Porphyromonas spp., but gemifloxacin was more potent than these agents against Fusobacterium and Mobiluncus spp.
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Gemifloxacin was the most potent agent against the Gram-positive anaerobes, particularly against Peptostreptococcus spp., Clostridium ramosum and Clostridium perfringens (Table IV) .
Discussion
Our results agree in general with those of others, [4] [5] [6] [7] [8] although we elected where possible to test strains known to have quinolone-resistance mechanisms and, therefore, they do not reflect clinical isolation rates.
Gemifloxacin is similar in potency to trovafloxacin, moxifloxacin and grepafloxacin, although there are small differences between these agents depending on the species tested. Gemifloxacin, moxifloxacin, trovafloxacin and grepafloxacin were more potent than ciprofloxacin against Gram-positive aerobes, and gemifloxacin was the most potent of the agents tested against streptococci-particularly ciprofloxacin-resistant pneumococci-and enterococci. Against most Gram-negative aerobes they are as potent as or slightly less potent than ciprofloxacin, but are more potent than ciprofloxacin against Acinetobacter spp. and S. maltophilia. Gemifloxacin, trovafloxacin, moxifloxacin and grepafloxacin were active against the majority of anaerobic bacteria and gemifloxacin was again the most potent agent tested against Gram-positive anaerobes. Based on in vitro activity there is little to choose between the new broad-spectrum quinolones although gemifloxacin is more potent, weight for weight, against pneumococci and, on this basis, might be the agent of choice for respiratory infections. Recent problems with toxicity have resulted in the withdrawal of some quinolones from clinical use and the role of gemifloxacin among the remaining agents will depend on pharmacokinetic data and safety profiles.
